Navigation Links
Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
Date:5/12/2009

- Presentation to Include Partnering Strategy and Process for Picoplatin -

SOUTH SAN FRANCISCO, Calif., May 12 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Ronald Martell, president and chief operating officer, will present at the BIO International Convention on Tuesday, May 19, at 3:20 p.m. Eastern Time in Atlanta. Mr. Martell will provide an overview of the Company's lead product candidate, picoplatin, and outline the Company's partnering strategy and process for picoplatin.

"We believe that picoplatin's potential for technical, clinical and regulatory success in small cell lung cancer and the upcoming proof-of-concept data in the colorectal and prostate cancers programs make the compound an attractive partnering asset to pharmaceutical and biotech companies," said Mr. Martell. "We are seeking a global development and commercialization partnership for picoplatin with co-development and U.S. co-promotion rights. This global partner would share our vision that picoplatin represents a pipeline in a product and enable us to maximize the value of picoplatin worldwide."

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinatio
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering.  ... is the in vitro growth of plant or animal ... and biopharmaceutical production. Cell culture is a crucial step ... and cell culture consumables are necessary for the in ...
(Date:7/24/2014)... Three companies from the angelMD network were ... Competition. Out of 700 competition entrants, Chiron Health, Litesprite, ... round. In this round twenty teams are invited to ... mentoring from thought-leaders and medical entrepreneurs from all over ... commitment to the Livestrong vision around the Big C ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... ANTONIO, March 30 BioMedical Enterprises, Inc. (BME), a ... development of orthopaedic memory metal implants, announced today that ... President, Sales and Marketing. BME specializes in nitinol ... bone ends together to promote bone union. The ...
... DIEGO, CA, March 30, 2009 Senomyx, Inc. (Nasdaq: ... using proprietary technologies to discover and develop novel flavor ... announced today the extension of the collaborative research phase ... Campbell Soup Company, a global manufacturer and marketer of ...
... final study data to FDA for cervical cancer vaccinePHILADELPHIA ... GSK ) today provided the following update regarding its ... for approval of CERVARIX(R), its vaccine to prevent cervical ... 16 and 18.GSK has submitted final data from its ...
Cached Biology Technology:BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing 2SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY 2SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY 3CERVARIX(R) U.S. Regulatory Update 2CERVARIX(R) U.S. Regulatory Update 3
(Date:7/25/2014)... 2014)The link between autism and disrupted brain development ... the disease, and is largely unknown. However, thanks ... Initiative (SFARI), George Washington University (GW) researcher Anthony-Samuel ... integrative and in-depth answers to these key questions ... LaMantia, professor of pharmacology and physiology at the ...
(Date:7/25/2014)... increasingly consume the healthcare community and remain ... , To address the worldwide crisis of ... countries, global leaders in diabetes, epidemiology and ... prevention and development of diverse intervention programs ... , This book on "Global Health Perspectives ...
(Date:7/25/2014)... tractography (DTT), which is derived from diffusion tensor ... motor tracts, such as the corticospinal tract, the ... The corticospinal tract is known to be a ... human brain. Several studies have reported on injury ... addition, some studies have demonstrated recovery of a ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... less than two weeks, Amanda Cobbs-Russell, a junior majoring in ... the adventure of a lifetime, requiring her to push herself ... of only five people two Americans and three Canadians ... to hike, eat, and sleep among sweeping glaciers, polar ice ...
... American Society for Microbiology (ASM) ICAAC Young Investigator Award ... College London. Sponsored by the ASM, this award ... and infectious diseases. Dr. Grndling,s initial work focused ... the membrane and how S monomers interact. She constructed ...
... state of upheaval, it is expected that they might take refuge ... milkshake? Not so, says Stacy L. Wood, Associate ... South Carolina. In fact, in a study to be published ... when people are in a state of upheaval, they,re more likely ...
Cached Biology News:UC Riverside student is 1 of only 5 persons selected for challenging Arctic expedition 2UC Riverside student is 1 of only 5 persons selected for challenging Arctic expedition 3
... NaCl, 20mM MOPS, pH 7.5, 60mM ... EGTA, 10 Properites: For selective in ... chromatography, divalent cation activation plus trypsin ... Assurance: routinely evaluated by dephosphorylation of ...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
Biology Products: